NantHealth and NantOmics to Present Data on Three-fold Overestimation of Tumor Mutation Burden Using Gene Panel vs Whole Exome at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

Results to be presented during the tumor biology session at the ASCO 2018 Annual Meeting CHICAGO, IL – June 4, 2018 – NantWorks, LLC today announced that its affiliate companies, NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based, personalized...

NantHealth and NantOmics to Share Data on Next-generation Sequencing of Paired DNA and RNA Analysis of Rare Tumors at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

Results to be presented during the tumor biology session at the ASCO 2018 Annual Meeting  CHICAGO, IL – June 4, 2018 – NantWorks, LLC today announced that its affiliate companies, NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based, personalized...

NantOmics to Present Data for Mutational Processes and Response to Neoadjuvant Chemotherapy in Breast Cancer at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

Genomic sequence analysis linked response to neoadjuvant therapy including Abraxane in triple negative breast cancer (TNBC) to a unique molecular signature.  The  results to be presented during the breast cancer session at ASCO 2018 Annual Meeting CHICAGO, IL – June...